CIA
NKTR icon

CSat Investment Advisory’s Nektar Therapeutics NKTR Stock Holding History

CSat Investment Advisory’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-29
Closed -$7K – 802
2020
Q3 		$7K Buy
29
+4
+16% +$1.26K ﹤0.01% 1073
2020
Q2 		$9K Sell
25
-31
-55% -$9.67K ﹤0.01% 1059
2020
Q1 		$15K Buy
56
+9
+19% +$2.78K ﹤0.01% 794
2019
Q4 		$15K Sell
47
-376
-89% -$109K ﹤0.01% 873
2019
Q3 		$115K Buy
423
+285
+207% +$105K 0.04% 288
2019
Q2 		$74K Buy
138
+49
+55% +$24.6K 0.03% 355
2019
Q1 		$45K Buy
89
+17
+24% +$10.1K 0.02% 173
2018
Q4 		$35K Buy
72
+53
+279% +$32K 0.02% 180
2018
Q3 		$17K Sell
19
-5
-21% -$4.27K 0.01% 256
2018
Q2 		$18K Buy
+24
New +$27.7K 0.01% 219

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

CSat Investment Advisory's NKTR Position: Q4 2020 in Review

CSat Investment Advisory sold out of Nektar Therapeutics (NKTR) in Q4 2020, closing a stake of 29 shares — an estimated $7K sold.

CSat Investment Advisory first reported a position in NKTR in Q2 2018 and held it in 10 quarters. The position peaked at $115K in Q3 2019. 246 funds tracked by Wall St. Rank hold NKTR as of Q4 2020.

  • CSat Investment Advisory reported no remaining Nektar Therapeutics position as of Q4 2020 after selling out during the quarter.
  • CSat Investment Advisory sold 29 Nektar Therapeutics shares in Q4 2020, an estimated $7K.
  • CSat Investment Advisory first reported a position in Nektar Therapeutics in Q2 2018 and held it in 10 quarters.
  • CSat Investment Advisory's Nektar Therapeutics position peaked at $115K in Q3 2019.
  • 246 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2020.

Based on CSat Investment Advisory's 13F filing for Q4 2020, filed 12 Feb 2021.